Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AUPHNASDAQ:AVIRNASDAQ:ELVNNASDAQ:NAGE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUPHAurinia Pharmaceuticals$8.64+0.1%$8.07$5.20▼$10.67$1.17B1.151.36 million shs4.36 million shsAVIRAtea Pharmaceuticals$3.45-2.3%$3.01$2.46▼$4.15$302.10M0.18321,108 shs444,473 shsELVNEnliven Therapeutics$20.68-3.9%$19.24$13.30▼$30.03$1.06B0.79299,814 shs1.44 million shsNAGENiagen Bioscience$14.22+2.9%$10.81$2.40▼$14.49$1.09B2.08884,291 shs2.46 million shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUPHAurinia Pharmaceuticals+0.12%+11.20%+8.27%+4.22%+56.81%AVIRAtea Pharmaceuticals-2.27%+6.15%+17.75%+17.75%+2.37%ELVNEnliven Therapeutics-3.90%-2.91%+28.69%-1.85%-2.36%NAGENiagen Bioscience+2.89%+5.80%+29.51%+110.04%+420.88%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAUPHAurinia Pharmaceuticals2.72 of 5 stars3.51.00.00.02.80.81.9AVIRAtea Pharmaceuticals2.7396 of 5 stars3.32.00.00.02.22.51.3ELVNEnliven Therapeutics2.2389 of 5 stars3.50.00.00.02.54.20.0NAGENiagen Bioscience1.4329 of 5 stars3.50.00.00.02.40.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAUPHAurinia Pharmaceuticals 3.00Buy$11.5033.10% UpsideAVIRAtea Pharmaceuticals 2.50Moderate Buy$6.0073.91% UpsideELVNEnliven Therapeutics 3.00Buy$39.6091.49% UpsideNAGENiagen Bioscience 3.00Buy$19.5037.13% UpsideCurrent Analyst Ratings BreakdownLatest AVIR, NAGE, AUPH, and ELVN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/16/2025ELVNEnliven TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$40.00 ➝ $52.006/16/2025ELVNEnliven TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$37.006/10/2025NAGENiagen BioscienceCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$13.00 ➝ $16.006/6/2025NAGENiagen BioscienceRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $23.005/27/2025NAGENiagen BioscienceCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$13.005/16/2025ELVNEnliven TherapeuticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$36.00 ➝ $27.005/15/2025ELVNEnliven TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$39.00 ➝ $40.004/11/2025AVIRAtea PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$6.20 ➝ $6.00(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAUPHAurinia Pharmaceuticals$235.13M4.96$0.31 per share27.98$2.68 per share3.22AVIRAtea PharmaceuticalsN/AN/AN/AN/A$5.20 per shareN/AELVNEnliven TherapeuticsN/AN/AN/AN/A$6.34 per shareN/ANAGENiagen Bioscience$99.60M11.25$0.06 per share233.65$0.60 per share23.70Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAUPHAurinia Pharmaceuticals$5.75M$0.2830.8615.43N/A16.11%14.27%9.93%7/30/2025 (Estimated)AVIRAtea Pharmaceuticals-$168.38M-$1.65N/AN/AN/AN/A-31.26%-29.27%8/6/2025 (Estimated)ELVNEnliven Therapeutics-$89.02M-$1.92N/AN/AN/AN/A-31.84%-30.09%8/12/2025 (Estimated)NAGENiagen Bioscience$8.55M$0.1783.65∞N/A13.07%19.06%12.20%N/ALatest AVIR, NAGE, AUPH, and ELVN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025ELVNEnliven Therapeutics-$0.51-$0.57-$0.06-$0.57N/AN/A5/12/2025Q1 2025AUPHAurinia Pharmaceuticals$0.08$0.16+$0.08$0.16$61.06 million$62.47 million5/12/2025Q1 2025AVIRAtea Pharmaceuticals-$0.56-$0.40+$0.16-$0.40N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAUPHAurinia PharmaceuticalsN/AN/AN/AN/AN/AAVIRAtea PharmaceuticalsN/AN/AN/AN/AN/AELVNEnliven TherapeuticsN/AN/AN/AN/AN/ANAGENiagen BioscienceN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAUPHAurinia Pharmaceuticals0.165.935.26AVIRAtea PharmaceuticalsN/A19.9419.94ELVNEnliven TherapeuticsN/A21.0721.06NAGENiagen BioscienceN/A3.663.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAUPHAurinia Pharmaceuticals36.83%AVIRAtea Pharmaceuticals86.67%ELVNEnliven Therapeutics95.08%NAGENiagen Bioscience15.41%Insider OwnershipCompanyInsider OwnershipAUPHAurinia Pharmaceuticals12.20%AVIRAtea Pharmaceuticals18.10%ELVNEnliven Therapeutics25.90%NAGENiagen Bioscience9.39%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAUPHAurinia Pharmaceuticals300135.10 million118.62 millionOptionableAVIRAtea Pharmaceuticals7085.58 million70.09 millionOptionableELVNEnliven Therapeutics5049.07 million36.36 millionOptionableNAGENiagen Bioscience12078.77 million71.37 millionN/AAVIR, NAGE, AUPH, and ELVN HeadlinesRecent News About These Companies2NAGE : Breaking Update: Wendy Tak Wing YU Engages In Options Exercise At Niagen...June 27 at 6:32 PM | benzinga.com1NAGE : Engaging In Insider Activity, Kristin Patrick At Niagen Bioscience Exercises...June 27 at 6:32 PM | benzinga.comMajor Update: Frank Jaksch Jr At Niagen Bioscience Exercises Options, Realizing $0June 26 at 4:41 PM | benzinga.comOptions Exercise Update At Niagen Bioscience: Ann Cohen Engages, Resulting In $0June 26 at 11:39 AM | benzinga.comSteven Rubin At Niagen Bioscience Exercises Options Worth $0June 26 at 11:39 AM | benzinga.comNiagen Bioscience, Inc. (NAGE) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comNiagen Biosciences: Anti-Aging Market Leader And Prime Beneficiary Of Long-Term Demographic TrendsJune 24, 2025 | seekingalpha.comEven though Niagen Bioscience (NASDAQ:NAGE) has lost US$55m market cap in last 7 days, shareholders are still up 623% over 3 yearsJune 23, 2025 | finance.yahoo.comNiagen Bioscience (NASDAQ:NAGE) Rating Increased to Strong-Buy at Wall Street ZenJune 22, 2025 | americanbankingnews.comNiagen Bioscience (NASDAQ:NAGE) Raised to Strong-Buy at Wall Street ZenJune 22, 2025 | marketbeat.comNiagen Bioscience, Inc: Niagen Bioscience to Participate at the Roth 15th Annual London ConferenceJune 20, 2025 | finanznachrichten.deNiagen Bioscience to Participate at the Roth 15th Annual London ConferenceJune 20, 2025 | businesswire.comNiagen Bioscience (NASDAQ:NAGE) Shares Down 2.4% - Should You Sell?June 18, 2025 | marketbeat.comNiagen Bioscience (NASDAQ:NAGE) Downgraded to Buy Rating by Wall Street ZenJune 14, 2025 | marketbeat.comChromaDex Corp (OCD1.DU)June 11, 2025 | nz.finance.yahoo.comNiagen Bioscience to Participate in the BIO 2025 International ConventionJune 11, 2025 | businesswire.comNiagen Bioscience: High Conviction, High ExpectationsJune 11, 2025 | seekingalpha.comCanaccord Genuity Group Forecasts Strong Price Appreciation for Niagen Bioscience (NASDAQ:NAGE) StockJune 10, 2025 | marketbeat.comNiagen Bioscience (NASDAQ:NAGE) Reaches New 1-Year High - Here's WhyJune 10, 2025 | marketbeat.comNiagen Bioscience Inc (NAGE) Announces Promising Clinical Study Results for Werner Syndrome ...June 9, 2025 | gurufocus.comNiagen Bioscience stock rises following positive clinical studyJune 9, 2025 | au.investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseASML Keeps Buying Back Its Own Stock—Chasing Discount and UpsideBy Gabriel Osorio-Mazilli | June 25, 2025View ASML Keeps Buying Back Its Own Stock—Chasing Discount and UpsideAnalysts Are Bullish on Marvell Stock Despite Amazon Deal ConcernBy Leo Miller | June 2, 2025View Analysts Are Bullish on Marvell Stock Despite Amazon Deal ConcernAVIR, NAGE, AUPH, and ELVN Company DescriptionsAurinia Pharmaceuticals NASDAQ:AUPH$8.64 +0.01 (+0.12%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$8.62 -0.02 (-0.23%) As of 06/27/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.Atea Pharmaceuticals NASDAQ:AVIR$3.45 -0.08 (-2.27%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$3.46 +0.01 (+0.43%) As of 06/27/2025 04:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.Enliven Therapeutics NASDAQ:ELVN$20.68 -0.84 (-3.90%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$20.68 0.00 (0.00%) As of 06/27/2025 05:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.Niagen Bioscience NASDAQ:NAGE$14.22 +0.40 (+2.89%) As of 06/27/2025 04:00 PM EasternNiagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Addition by Subtraction: Intel’s New Strategy Energizes Investors NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Super Micro’s Bold $2B Bond Plan Signals 35% Premium Upside QuantumScape Soars 30%: What Drove the Next-Gen EV Stock's Rally Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
